Cargando…

SAT-001 Clinically Meaningful Effects of E2/P4 Oral Capsule in Treating Vasomotor Symptoms

Hormonal therapies effectively reduce the frequency and severity of vasomotor symptoms (VMS) in menopausal women; however, whether the effect is clinically meaningful to women is typically not determined. Oral estradiol/progesterone (E2/P4; mg/mg) 1/100 and 0.5/100 significantly improved moderate to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Constantine, Ginger, Graham, Shelli, Revicki, Dennis A, Kagan, Risa, Mirkin, Sebastian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Reproductive Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7208865/ http://dx.doi.org/10.1210/jendso/bvaa046.438

Ejemplares similares

SAT-021 Effects of E2/P4 Oral Capsules on Bone Turnover in Women with Vasomotor Symptoms
por: Constantine, Ginger, et al.
Publicado: (2020)

SAT-237 Combined Bioidentical Estradiol and Progesterone Capsules Improved Quality of Sleep in Postmenopausal Women with Vasomotor Symptoms
por: Santoro, Nanette, et al.
Publicado: (2019)

SAT-238 Predictors Of Vaginal/Uterine Bleeding With Oral TX-001HR (Estradiol and Progesterone) Capsules Taken For Menopausal Vasomotor Symptoms
por: Constantine, Ginger, et al.
Publicado: (2019)

Evaluation of clinical meaningfulness of estrogen plus progesterone oral capsule (TX-001HR) on moderate to severe vasomotor symptoms
por: Constantine, Ginger D., et al.
Publicado: (2019)

TX-001HR is associated with a clinically meaningful effect on severity of moderate to severe vasomotor symptoms in the REPLENISH trial
por: Constantine, Ginger D., et al.
Publicado: (2020)

Effects of E2/P4 oral capsules on bone turnover in women with vasomotor symptoms
por: McClung, Michael R., et al.
Publicado: (2022)

17β-estradiol/progesterone in a single, oral, softgel capsule (TX-001HR) significantly increased the number of vasomotor symptom-free days in the REPLENISH trial
por: Kaunitz, Andrew M., et al.
Publicado: (2020)

Relationship between vasomotor symptom improvements and quality of life and sleep outcomes in menopausal women treated with oral, combined 17β-estradiol/progesterone
por: Mirkin, Sebastian, et al.
Publicado: (2019)

Improvement in sleep outcomes with a 17β-estradiol–progesterone oral capsule (TX-001HR) for postmenopausal women
por: Kagan, Risa, et al.
Publicado: (2018)

Oral 17β-estradiol/progesterone (TX-001HR) and quality of life in postmenopausal women with vasomotor symptoms
por: Simon, James A., et al.
Publicado: (2019)

Estradiol and progesterone bioavailability for moderate to severe vasomotor symptom treatment and endometrial protection with the continuous-combined regimen of TX-001HR (oral estradiol and progesterone capsules)
por: Lobo, Rogerio A., et al.
Publicado: (2019)

SAT-239 Bioidentical Estradiol and Progesterone Improved Hot Flushes, Night Sweats and Sweating
por: Liu, James, et al.
Publicado: (2019)

SAT-LB003 Nonsmokers Benefit from Lower Doses of an Estradiol/Progesterone Combination: Results of the REPLENISH Trial
por: Constantine, Ginger, et al.
Publicado: (2019)

PMON281 PERSISTENT VIRILIZATION AND VASOMOTOR SYMPTOMS IN A TRANSMAN 5-YEARS POST TESTOSTERONE WITHDRAWAL
por: Nemati, Maryam, et al.
Publicado: (2022)

SAT-013 Segesterone Acetate (SA) Serum Levels with a Statistical Model of Continued Use of the SA/Ethinyl Estradiol (EE) Contraceptive Vaginal System
por: Liu, James H, et al.
Publicado: (2020)

SAT-219 A Novel 1-Year Contraceptive Vaginal System Delivering Segesterone Acetate and Ethinyl Estradiol: Effects on Lipids and other Hepatic Proteins
por: Archer, David, et al.
Publicado: (2019)

OR06-5 Fezolinetant for Treatment of Moderate-to-severe Vasomotor Symptoms Associated with Menopause: Results from a 52-week Study (Skylight 2)
por: English, Marci, et al.
Publicado: (2022)

Visual improvements in vaginal mucosa correlate with symptoms of VVA: data from a double-blind, placebo-controlled trial
por: Simon, James A., et al.
Publicado: (2017)

SAT-026 Association of Inflammatory Markers with Depressive Symptoms Across the Perinatal Period
por: Braybrook, Emma, et al.
Publicado: (2020)

OR33-6 The Neurokinin 3 Receptor Antagonist, Fezolinetant, Is Effective in Treatment of Menopausal Vasomotor Symptoms: A Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study
por: Fraser, Graeme, et al.
Publicado: (2019)

Endometrial safety and bleeding profile of a 17β-estradiol/progesterone oral softgel capsule (TX-001HR)(∗)
por: Mirkin, Sebastian, et al.
Publicado: (2020)

SAT-034 The Effect of Natesto on Spermatogenesis, Reproductive Hormones, and Hypogonadal Symptoms. A Phase IV Study
por: Masterson, Thomas A, et al.
Publicado: (2020)

A Simple Algorithm is Created for Identifying Intermenstrual Intervals Containing an Oscillatory LH Pattern That Associates With Vasomotor Symptoms Using Daily Urinary LH Excretion in the Study of Women’s Health Across the Nation (SWAN)
por: Lasley, Bill L, et al.
Publicado: (2021)

SAT-221 False-Positive Urinary Free Cortisol with Oral Contraceptive Use
por: Lavelle, Kristen, et al.
Publicado: (2019)

SAT-220 Oral Contraceptives and Their Effect on the Evaluation of Cushing's Syndrome: A Case Report
por: Ng, Zhi Guang, et al.
Publicado: (2019)

SAT383 Case Study: Impact of Weight Reduction and Oral Contraceptive Pills on Hyperandrogenism
por: Syeda, Asma, et al.
Publicado: (2023)

SAT-196 Maternal immunity: Preimplantation Preparation
por: Elbert, Ashleigh, et al.
Publicado: (2019)

SUN-001 Identification of Dehydroepiandrosterone-s (DHEA-s) Elevation Due to Performance Enhancing Supplements
por: Shin, Terry, et al.
Publicado: (2020)

MON-001 Peripartum Sertraline (Zoloft®) Increases Pup Mortality Immediately Postpartum
por: Sheftel, Celeste, et al.
Publicado: (2020)

THU001 Novel Interactive Text-messaging Curriculum For Endocrinology Board Review
por: Majety, Priyanka, et al.
Publicado: (2023)

SAT-LB042 Effect of Dehydroepiandrosterone on the Perimenopausal Ovary
por: Luna, Selva, et al.
Publicado: (2019)

SAT-233 Management of Pregestational Diabetes Insipidus in Pregnancy
por: Venkataraman, Sandhya, et al.
Publicado: (2019)

SAT-213 Late Diagnosis of Complete Androgen Insensitivity
por: Tsai, Karen, et al.
Publicado: (2019)

SAT-036 Redefining Eunuchoid Body Proportions in Adults
por: Singh, Santosh Kumar
Publicado: (2020)

OR11-03 NT-814, a Non-Hormonal Dual Neurokinin 1,3 Receptor Antagonist Markedly Improves Vasomotor Symptoms in Post-Menopausal Women; Results of a Randomised, Double-Blind, Placebo-Controlled, Dose-Finding Study (SWITCH-1)
por: Simon, James, et al.
Publicado: (2020)

SAT-040 Changes in Metabolic Parameters After Administration of Novel Oral Androgens with Progestational Activity for 28 Days
por: Yuen, Fiona, et al.
Publicado: (2020)

SAT-LB1 Detection of Serum Macro-Luteinizing Hormone
por: Ogura-Ochi, Kanako, et al.
Publicado: (2020)

SAT-LB5 Prevalence of Hypogonadism in Young Obese Males
por: Halappanavar, Anup, et al.
Publicado: (2020)

SAT-016 Analytical Performance and Clinical Value of AMH Testing
por: Sluss, Patrick M, et al.
Publicado: (2020)

MON-LB001 Ovulation Induction Results in Altered Growth and Metabolic Dysfunction in Mice Offspring
por: Harner, Royce, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tsoh54j5383ust6haao1ap8s5m